Volume 10, Issue 8 pp. 970-973

What delay should there be between primary infectious mononucleosis and renal transplantation?

L. Kerecuk

L. Kerecuk

Department of Paediatric Nephrology, Royal Manchester Children's Hospital, Manchester, UK

Search for more papers by this author
P. Amlot

P. Amlot

Department of Immunology, Royal Free Hospital, London, UK

Search for more papers by this author
H. Riad

H. Riad

Renal Transplant Unit, Manchester Royal Infirmary, Manchester, UK

Search for more papers by this author
N. J. A. Webb

N. J. A. Webb

Department of Paediatric Nephrology, Royal Manchester Children's Hospital, Manchester, UK

Search for more papers by this author
First published: 26 May 2006
Citations: 2
Larissa Kerecuk, Department of Paediatric Nephrology, Evelina Children's Hospital, Guy's and St Thomas’ NHS Foundation Trust, Lambeth Palace Road, London SE1 7EH, UK
Tel.: +44 0 207 188 4587
Fax: +44 0 207 188 4591
E-mail: [email protected]

Abstract

Abstract: A 17-yr-old girl in end-stage renal failure was due to undergo living-related pre-emptive renal transplantation when she developed acute infectious mononucleosis (AIM) from Epstein–Barr virus (EBV). In view of the risk of post-transplant lymphoproliferative disorder (PTLD) we were unsure as to the optimal delay between AIM and renal transplantation. This report describes the process used to determine maturation of the immune response to EBV using a combination of serology, immunophenotyping and molecular viral load estimation. These tests showed that EBV had not been cleared and dialysis was instituted rather than proceed directly to transplantation. After EBV viral load became undetectable in the blood, living-related donor was successfully performed 13 months after AIM. With 42-month post-transplant follow up there has been no evidence of PTLD.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.